London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
im afraid they knew exactly what they have /are doing. They are only getting away with camoflauge due probably to most of them working remotely. Very good excuse. how many brokers/spivs do you know that are working from a centralised regulated office ???, maybe hopefully a lot of them will retire, but white collar crime will not go un noticed in the long term inmv . this if anything will become more highlighted than ever in the future. I wonder how many FDA breaches have occurred recently across the markets. The good old fca must have a huge backlog across the so called regulated market by now.onmho so dyor
Trickymatters: Good summary ! Certainly, the Guy's/St. Thomas'/Kings College study will require both a much larger cohort and repeated testing over years if it is to be regarded as a significant longitudinal study. You make a good point about possible very long-term immunity granted by exposure to pathogens when we are very young. However, it would not be correct to say that exposure in the very aged to the 1918/1919 pandemic might imbue immunity to the SARS-CoV-2 virus as that pandemic was caused by an H1N1 virus. Safy: I think you've answered your own questions about how antibody testing would need to complement any vaccination programme. There would need to be extensive pre-vaccination antibody testing, followed up by regular (3 to 6-monthly?) repeat antibody testing after vaccination. Again, a proper scientific protocol would demand that any studies be of a large cohort and extended over a long period to give scientifically valid longitudinal data. Some investors may regard ODX as a proxy for forthcoming vaccines. Interesting that, today, the FDA granted fast-track approval for two vaccines being developed by Pfizer and BioNTech. Several vaccines are already in human trials. This is evidence that the normal slow pace of vaccine development and trials WILL be accelerated. Apart from the modest benefit from Remdesivir, there is no clinically accepted treatment for Covid-19 infection and this vacuum will put pressure on the development/approval of vaccines. On two other issues: Richard Sneller's (Oryx) offloading seems rather badly timed. FinnCap need to up their game. Secondly, totally agree that Colin King needs to give Paul McManus of Walbrook PR something of a rocket. Whilst King prefers to under-promise and over-perform, there is no excuse for slap-dash publicity material. Something to raise with King/McManus during the conference podcast, methinks. All in my opinion only. Please keep safe !
The two studies cited critically on this have both been small studies. The Guardian called the King's college study a 'longitudinal' study. We've only had the disease for less than a year so it's hardly longitudinal. Leon Feinstein did a seminal 'longitudanal' study looking at children's development in relation to socio-economic background- for 22 years. Just one example of having a journo write up research- not really their field, much as I respect the good old Guardian. Our test will capture any level of antibodies. They are using tests available from March- May- the RTC's is better on accuracy and specificity than any others- which is it's big USP alongside it's accessibility as a home testing kit. Professor Bell has raised the question of diminishing antibodies ages ago. It doesn't reduce the value of knowing whether you had it- detecting the antibodies even at low levels. No-one in the whole world has ever had it twice. No-one has had any SARs 2 virus twice. Centenarians are doing pretty well compared to over 90 year olds- they think because there's an immune memory from the Spanish flu, protecting many of them. So the issue is not that you will get it twice in a short time but if your antibodies are diminishing what is protecting you? They think that alongside the antibodies you have a t cell response and this is what may be providing the lasting immunity. So they are looking at that. It's significant for vaccine development - it's not about reducing the value of anti-body testing. No vaccine lasts forever. If it means it's more challenging to get a vaccine- great shame for the world. Ditto if you need a booster every few months because of the implications for the developing world. More costly. It does mean we will need test and trace longer. Sentiment is going to be affected every time some-one says they have a vaccine that makes them hopeful. Which some-one has said today. Of course sentiment will be affected by that because we're all desperate for this to be over and hope is our default position emotionally. But these studies are saying ain't going to be easy to get a vaccine. That's all they are saying imo. The rest is noise.
The spanish study is interesting it indicates 14% may have lost protection but qualified this by saying it could be due in part to false negatives. It also indicated the idea of acheiving herd immunity would be difficult. Of even more intrest it said using reliable point of care antidody testing was the way forward for further the mass studies to understand the disease further.
I can see the logic in testing of coarse . But I can’t follow your faith in antibody testing.it now after two separate study’s(Links above) and another from northern Italy Would appear to have a large ? Mark developing . Do not get me wrong I believe in testing and obviously it would be great if once you’ve had Covid you become immune , but that would appear not to be the case. Still if the anti body test can confirm if you have the virus and do it at home and cheap then that is something. I read that a New Jersey company has developed a spit test that gives results in 30 minits. Early doors re testing .
It actually means the need for a quick at home cheap antibody test is even bigger than we thought - regular testing is required - and even better if its attached to an app so results can be tracked and monitored in BULK This will be the same for testing after a vaccine comes onto the market (if it does)